FDA Approves InspireMD’s CGuard Prime for TCAR, Six Months After a Delivery-System Recall

Photo: National Cancer Institute / Unsplash

The approval rests on a 50-patient single-arm study, and the company's latest quarterly filing says there is substantial doubt about its ability to keep operating.

Background

InspireMD's CGuard Prime is a self-expanding nitinol carotid stent covered by MicroNet, a permanent micromesh meant to trap plaque and thrombus against the vessel wall [1][4]. Endovascular Today described the mesh as a single 20-micron polyethylene terephthalate strand [4]. The FDA granted premarket approval (PMA) to the 135 cm transfemoral version, used for carotid artery stenting (CAS), on June 23, 2025 [3], and the company announced its U.S. commercial launch on July 9, 2025 [4].

Less than a year later, the rollout stalled. On May 1, 2026, InspireMD announced a voluntary U.S. recall of the CGuard Prime 135 cm delivery system, initiated in consultation with the FDA, after a controlled launch showed the system's technical success during stenting did not meet expectations [2]. The company said the recall did not involve the stent implant and had no safety implications for patients who had already received one. It also withdrew its full-year 2026 revenue guidance [2]. According to the third-quarter 10-Q, the recall reduced revenue by about $734,000 and led to about $612,000 in inventory impairment, and U.S. revenue fell to $32,000 for the quarter [3].

What Happened

On Nov. 12, InspireMD announced that the FDA had approved its PMA supplement for the CGuard Prime TransCarotid Stent System [1]. The system uses an 80 cm delivery system and is approved for transcarotid artery revascularization (TCAR) with an embolic protection system specified in its labeling. It is indicated to improve carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy [1]. Because the recalled CAS delivery system is still off the market, the approval gives InspireMD a U.S.-approved CGuard Prime configuration it can sell again. The release did not give a launch date.

The company expects the TCAR approval to double the platform's total addressable U.S. market. It cites more than 35,000 TCAR procedures performed annually in the U.S. and, by its own estimate, about 75,000 carotid stenting procedures a year across TCAR and CAS [1]. Chief executive Marvin Slosman called the approval "a major milestone for InspireMD" [1]. These market figures are the company's own projections, not independent analyses.

Study Design and Limitations

The approval rests on CGUARDIANS II, a prospective, multicenter, single-arm U.S. study that enrolled 50 pivotal high-surgical-risk patients at 11 sites. All procedures used the FDA-cleared ENROUTE Transcarotid Neuroprotection System [1]. According to the company, the study achieved 100% acute device success and recorded no deaths, strokes, myocardial infarctions or stent thrombosis at 30 days, with complete stent patency in evaluable patients [1].

Those numbers are clean but limited. The study had no comparison arm, the reported outcomes run only to 30 days, and with 50 patients it is too small to rule out uncommon complications. The results come from a company press release; VBN did not find a peer-reviewed publication of the pivotal data. The phrase "evaluable patients" also suggests that not every patient contributed patency data, and the release does not say how many did.

The company's finances are also a concern. In its 10-Q for the quarter ended Sept. 30, signed Nov. 16, InspireMD said there is substantial doubt about its ability to continue as a going concern and that it does not have enough resources to fund operations for at least the next 12 months [3]. It reported $19.2 million in cash and cash equivalents, third-quarter revenue of $2.2 million, a third-quarter net loss of $9.8 million, and a nine-month net loss of $37.8 million [3]. The filing also disclosed a public offering that closed Nov. 16 with gross proceeds of about $37.5 million before fees [3]. The release's forward-looking statements list recall-related risks, including possible customer and patient lawsuits [1]. A stent built for sustained embolic protection now has to be sold by a company working on more sustained financial protection.

What Comes Next

InspireMD says it is testing design changes to the 135 cm delivery system and expects to submit a PMA supplement to the FDA in the fourth quarter of 2026. It also cautions in its 10-Q that it may not be able to resume U.S. commercialization of that system [3]. The company is also running CGUARDIANS III, a pivotal trial of SwitchGuard, its investigational transcarotid neuroprotection system, which enrolled its first patient in June 2026 [1][3]. It plans a proprietary micropuncture access kit for TCAR as well [1]. For vascular surgeons and interventionalists, the more useful data will be longer-term stroke and patency outcomes in larger groups of TCAR patients.

This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.

References

  1. InspireMD, Inc. InspireMD Announces FDA Approval of the CGuard Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures. Press release, Exhibit 99.1 to Form 8-K, U.S. Securities and Exchange Commission. Nov 12, 2026. https://www.sec.gov/Archives/edgar/data/0001433607/000149315226051453/ex99-1.htm

  2. InspireMD, Inc. InspireMD Initiates Voluntary U.S. Recall of CGuard Prime 135 cm Carotid Stent Delivery System. Press release, Exhibit 99.1 to Form 8-K, U.S. Securities and Exchange Commission. May 1, 2026. https://www.sec.gov/Archives/edgar/data/0001433607/000149315226020891/ex99-1.htm

  3. InspireMD, Inc. Form 10-Q for the quarterly period ended September 30, 2026. U.S. Securities and Exchange Commission. Signed Nov 16, 2026. https://www.sec.gov/Archives/edgar/data/0001433607/000149315226052402/form10-q.htm

  4. Endovascular Today. InspireMD's CGuard Prime Carotid Stent System Launched in United States. July 2025. https://evtoday.com/news/inspiremds-cguard-prime-carotid-stent-system-launched-in-united-states

Katie Coffee

Professional photographer, Medical journalist, Business Development & Head of Marketing at Innovative Vascular Institute, from Louisiana, to Nashville. Medical PR

https://katiecoffeephoto.com
Previous
Previous

Medtronic to Buy Contego Medical for $380 Million, Days After FDA Approves Its Carotid System

Next
Next

Jacksonville Pharmacy Owner and Accountant Indicted in Alleged $51 Million HIV PEP Billing Scheme